Hyperhomocysteinemia, MTHFR, and risk of vascular disease (letter) by Blom, H.J. & Verhoef, P.
Letters to the Editor must not exceed 400 words in length and must be limited to three authors and five references. They should not have
tables or figures and should relate solely to an article published in Circulation within the preceding 12 weeks. Authors of letters selected
for publication will receive prepublication proofs, and authors of the article cited in the letter will be invited to reply. Replies must be
signed by all authors listed in the original publication. Please submit three typewritten, double-spaced copies of the letter to Herbert L.
Fred, MD, 0 the Circulation Editorial Office. Letters will not be returned.
Hyperhomocysteinemia, MTHFR, and Risk of
Vascular Disease
To the Editor:
In contrast to data derived from many epidemiological stud-
ies,1 Brattstro¨m et al2 conclude that mild hyperhomocysteinemia
is not causally related to the pathogenesis of vascular disease.
Their conclusion is based on a meta-analysis of 23 studies in
which they observed no significant increased risk of vascular
disease among subjects with the TT genotype for the MTHFR
C677T polymorphism (a common mutation that raises total
homocysteine [tHcy] in plasma) compared with those with the
CC genotype.
In our opinion, the authors have overlooked several crucial
aspects:
1. They calculated that subjects with the MTHFR TT genotype
have plasma tHcy concentrations 2.6 mmol/L higher than those
with the CC genotype. Presuming that an increase in plasma tHcy
of 1 mmol/L is associated with approximately a 10% increase in
risk of vascular disease,1 the expected odds ratio (OR) for the TT
genotype compared with the CC genotype is 1.26. This is well
within the 95% CI Brattstro¨m et al calculated (OR 1.12 [95% CI
0.92 to 1.37]). Therefore, their study does not prove or disprove
whether TT genotype is associated with increased risk of
vascular disease.
2. MTHFR regulates availability of 1-carbon units of folate not
only for remethylation of homocysteine, but also for synthesis of
thymidine and purines. Reduced MTHFR activity will hamper
homocysteine remethylation but lead to higher availability of
folate for DNA synthesis.3,4 The latter may be beneficial during
cell division, eg, during repair of endothelial damage. Indeed,
endothelial cells with the TT genotype in culture grow faster than
those with the other MTHFR genotypes (H.J. Blom and E.F. van
der Molen, unpublished observation, 1998).
3. It is not unlikely that the TT genotype emerges as a risk
factor for vascular disease mainly in populations with low-
normal folate intake, considering that it results in moderate
hyperhomocysteinemia mainly in subjects with suboptimal folate
status.5 In fact, from the data presented by Brattstro¨m et al,2 it
appears that this polymorphism is directly associated with
vascular disease more often in European than North American
studies. This may be explained in part by the fact that use of
multivitamin supplements and fortification of grain products
with folic acid is much more common in the United States/
Canada than in Europe.
We are currently gathering original data of observational
studies on the relationship between this polymorphism and risk
of coronary heart disease (CHD). We will study whether the TT
genotype is associated with a beneficial CHD risk profile, eg,
low blood pressure. Preliminary results are expected in the
summer of 2000.
Within 2 to 4 years, clinical trials of tHcy lowering by
supplementation with folic acid (and vitamins B6 and B12) will be
completed. Conceivably, these trials cannot prove a causal role
of elevated plasma tHcy, as there is still a possibility that low
vitamin status itself is the primary cause of vascular disease and
elevation of plasma tHcy levels just a marker of low vitamin
status. The premature conclusions drawn by Brattstro¨m et al
could direct public health attention away from the possibly
important role of folate and the other B vitamins.
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